Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $80,900 | $39,099 | $21,351 | $375,048 |
| - Cash | $6,212 | $20,752 | $44,579 | $69,724 |
| + Debt | $14,811 | $13,814 | $453 | $1,161 |
| Enterprise Value | $89,499 | $32,161 | -$22,775 | $306,485 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$35,984 | -$26,820 | -$50,986 | -$89,974 |
| % Margin | – | – | – | – |
| Net Income | -$56,828 | -$31,385 | -$51,660 | -$89,945 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.31 | -0.84 | -1.54 | -3.03 |
| % Growth | -56% | 45.5% | 49.2% | – |
| Operating Cash Flow | -$31,904 | -$18,292 | -$44,038 | -$62,932 |
| Capital Expenditures | -$257 | -$160 | -$133 | -$180 |
| Free Cash Flow | -$32,161 | -$18,452 | -$44,171 | -$63,112 |